Want to stay up-to-date on the very latest developments in non-malignant haematology? Don't have the time or skills to critically appraise important papers? Join Pip and Rich, two haematology doctors on a journey of learning and discovery. Each episode, they will discuss a seminal trial, critically appraise the paper, interview a study author, and discuss the implications of the trial on clinical practice with a subject expert. CPD credits are available from RCPath. The podcast is sponsored by Sobi as a hands-off educational grant. Sobi have no editorial input whatsoever.
This podcast helps you to go beyond the abstract, delving deep into the methods, results, subanalyses, and implications. Interviews with authors gives a real-life perspective on the running of a clinical trial allowing explanations of why they did what they did and good honest discussion on limitations and how they might do it differently next time.
Hosted on Acast. See acast.com/privacy for more information.
Want to stay up-to-date on the very latest developments in non-malignant haematology? Don't have the time or skills to critically appraise important papers? Join Pip and Rich, two haematology doctors on a journey of learning and discovery. Each episode, they will discuss a seminal trial, critically appraise the paper, interview a study author, and discuss the implications of the trial on clinical practice with a subject expert. CPD credits are available from RCPath. The podcast is sponsored by Sobi as a hands-off educational grant. Sobi have no editorial input whatsoever.
This podcast helps you to go beyond the abstract, delving deep into the methods, results, subanalyses, and implications. Interviews with authors gives a real-life perspective on the running of a clinical trial allowing explanations of why they did what they did and good honest discussion on limitations and how they might do it differently next time.
Hosted on Acast. See acast.com/privacy for more information.
Prof. Isabelle Mahé is a cardiologist, triallist, and Professor of Internal Medicine Paris Cité University, France. She recently led the API-CAT study, a randomised controlled trial of apixaban 2.5 mg BD vs 5 mg BD for treatment of patients with cancer associated venous thromboembolism after 6 months of therapy. Pip and Rich discussed API-CAT in detail in episode 20 and now seize the opportunity to speak to an international expert and leader in the field about the art of the trial.
API-CAT was published in the New England Journal of Medicine in 2025,
Hosted on Acast. See acast.com/privacy for more information.